CN102727882B - 猪繁殖与呼吸综合征、猪瘟、伪狂犬病的三联活疫苗及其制备方法 - Google Patents
猪繁殖与呼吸综合征、猪瘟、伪狂犬病的三联活疫苗及其制备方法 Download PDFInfo
- Publication number
- CN102727882B CN102727882B CN201110331159.8A CN201110331159A CN102727882B CN 102727882 B CN102727882 B CN 102727882B CN 201110331159 A CN201110331159 A CN 201110331159A CN 102727882 B CN102727882 B CN 102727882B
- Authority
- CN
- China
- Prior art keywords
- vaccine
- pseudorabies
- swine fever
- tcid
- porcine reproductive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 414
- 241000282898 Sus scrofa Species 0.000 title claims abstract description 158
- 206010037660 Pyrexia Diseases 0.000 title claims abstract description 113
- 208000009305 pseudorabies Diseases 0.000 title claims abstract description 96
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 238000011081 inoculation Methods 0.000 claims abstract description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 26
- 230000002265 prevention Effects 0.000 claims abstract description 8
- 241000700605 Viruses Species 0.000 claims description 121
- 210000004027 cell Anatomy 0.000 claims description 116
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 claims description 111
- 239000003440 toxic substance Substances 0.000 claims description 56
- 231100000614 poison Toxicity 0.000 claims description 53
- 239000007788 liquid Substances 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 38
- 230000001717 pathogenic effect Effects 0.000 claims description 38
- 239000002773 nucleotide Substances 0.000 claims description 36
- 125000003729 nucleotide group Chemical group 0.000 claims description 36
- 238000011218 seed culture Methods 0.000 claims description 33
- 239000000427 antigen Substances 0.000 claims description 29
- 108091007433 antigens Proteins 0.000 claims description 29
- 102000036639 antigens Human genes 0.000 claims description 29
- 206010008631 Cholera Diseases 0.000 claims description 28
- 230000003612 virological effect Effects 0.000 claims description 26
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 23
- 230000001524 infective effect Effects 0.000 claims description 23
- 238000004321 preservation Methods 0.000 claims description 22
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 16
- 230000001861 immunosuppressant effect Effects 0.000 claims description 16
- 239000003018 immunosuppressive agent Substances 0.000 claims description 16
- 239000003381 stabilizer Substances 0.000 claims description 15
- LXWYCLOUQZZDBD-LIYNQYRNSA-N csfv Chemical group C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LXWYCLOUQZZDBD-LIYNQYRNSA-N 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 231100000167 toxic agent Toxicity 0.000 claims description 12
- 230000000813 microbial effect Effects 0.000 claims description 11
- 230000002779 inactivation Effects 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 239000002574 poison Substances 0.000 claims description 9
- 238000010166 immunofluorescence Methods 0.000 claims description 8
- 239000002435 venom Substances 0.000 claims description 8
- 231100000611 venom Toxicity 0.000 claims description 8
- 210000001048 venom Anatomy 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 7
- 239000002054 inoculum Substances 0.000 claims description 6
- 238000012423 maintenance Methods 0.000 claims description 6
- 101800001728 Nsp1 Proteins 0.000 claims description 5
- 238000004113 cell culture Methods 0.000 claims description 5
- 229940030156 cell vaccine Drugs 0.000 claims description 5
- 101150072564 gE gene Proteins 0.000 claims description 5
- 238000003306 harvesting Methods 0.000 claims description 4
- 210000003501 vero cell Anatomy 0.000 claims description 4
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000000413 hydrolysate Substances 0.000 claims description 2
- 238000005096 rolling process Methods 0.000 claims description 2
- 238000004114 suspension culture Methods 0.000 claims description 2
- 230000036039 immunity Effects 0.000 abstract description 30
- 230000001900 immune effect Effects 0.000 abstract description 15
- 201000010099 disease Diseases 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 11
- 206010033799 Paralysis Diseases 0.000 abstract description 6
- 230000003053 immunization Effects 0.000 abstract description 6
- 238000002649 immunization Methods 0.000 abstract description 5
- 230000005847 immunogenicity Effects 0.000 abstract description 5
- 230000002829 reductive effect Effects 0.000 abstract description 3
- 206010062016 Immunosuppression Diseases 0.000 abstract 1
- 230000002480 immunoprotective effect Effects 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 77
- 238000012360 testing method Methods 0.000 description 60
- 230000029058 respiratory gaseous exchange Effects 0.000 description 47
- 208000011580 syndromic disease Diseases 0.000 description 47
- 230000001850 reproductive effect Effects 0.000 description 46
- 241001465754 Metazoa Species 0.000 description 37
- 108090000623 proteins and genes Proteins 0.000 description 33
- 206010015856 Extrasystoles Diseases 0.000 description 27
- 238000010171 animal model Methods 0.000 description 26
- 230000001681 protective effect Effects 0.000 description 25
- 241000710777 Classical swine fever virus Species 0.000 description 19
- 238000003860 storage Methods 0.000 description 18
- 238000002347 injection Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 13
- 238000010255 intramuscular injection Methods 0.000 description 11
- 239000007927 intramuscular injection Substances 0.000 description 11
- 206010025482 malaise Diseases 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 210000004748 cultured cell Anatomy 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000001018 virulence Effects 0.000 description 8
- 208000035473 Communicable disease Diseases 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical class [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 6
- 231100000957 no side effect Toxicity 0.000 description 6
- 239000002356 single layer Substances 0.000 description 6
- 235000015921 sodium selenite Nutrition 0.000 description 6
- 238000004448 titration Methods 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 102000001253 Protein Kinase Human genes 0.000 description 5
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 5
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 229940031567 attenuated vaccine Drugs 0.000 description 5
- 230000008034 disappearance Effects 0.000 description 5
- 241001493065 dsRNA viruses Species 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 108060006633 protein kinase Proteins 0.000 description 5
- 108010076039 Polyproteins Proteins 0.000 description 4
- 241000282887 Suidae Species 0.000 description 4
- 230000003712 anti-aging effect Effects 0.000 description 4
- 229910052785 arsenic Inorganic materials 0.000 description 4
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000009849 deactivation Effects 0.000 description 4
- 230000001079 digestive effect Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 210000003754 fetus Anatomy 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 239000005723 virus inoculator Substances 0.000 description 4
- 206010000234 Abortion spontaneous Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102100023933 Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial Human genes 0.000 description 3
- 206010021703 Indifference Diseases 0.000 description 3
- 241000204031 Mycoplasma Species 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 108010011219 dUTP pyrophosphatase Proteins 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 208000015994 miscarriage Diseases 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000009781 safety test method Methods 0.000 description 3
- 229960001471 sodium selenite Drugs 0.000 description 3
- 239000011781 sodium selenite Substances 0.000 description 3
- 208000000995 spontaneous abortion Diseases 0.000 description 3
- 231100000041 toxicology testing Toxicity 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 239000000273 veterinary drug Substances 0.000 description 3
- 101710202747 Alkaline nuclease Proteins 0.000 description 2
- 208000001726 Classical Swine Fever Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000710781 Flaviviridae Species 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 101150001779 ORF1a gene Proteins 0.000 description 2
- 241000710778 Pestivirus Species 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 101001042081 Suid herpesvirus 1 (strain Indiana-Funkhauser / Becker) E3 ubiquitin-protein ligase ICP0 Proteins 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 239000012930 cell culture fluid Substances 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 239000000701 coagulant Substances 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 230000002498 deadly effect Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 230000004938 stress stimulation Effects 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 description 1
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
- 101150096316 5 gene Proteins 0.000 description 1
- 241001516864 Allende Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 101150026402 DBP gene Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 101150047390 MCP gene Proteins 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241000871677 PRRSV VR2332 Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 208000016253 exhaustion Diseases 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000005571 horizontal transmission Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000012153 swine disease Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Abstract
Description
Claims (31)
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110331159.8A CN102727882B (zh) | 2011-10-27 | 2011-10-27 | 猪繁殖与呼吸综合征、猪瘟、伪狂犬病的三联活疫苗及其制备方法 |
PCT/CN2012/076125 WO2012163258A1 (en) | 2011-05-27 | 2012-05-25 | Combined vaccines for prevention of porcine virus infections |
TW101118902A TWI579297B (zh) | 2011-05-27 | 2012-05-25 | 用於預防豬病感染之混合疫苗 |
CA2837125A CA2837125A1 (en) | 2011-05-27 | 2012-05-25 | Combined vaccines for prevention of porcine virus infections |
KR1020137034298A KR20140036262A (ko) | 2011-05-27 | 2012-05-25 | 돼지 바이러스 감염의 예방을 위한 혼합 백신 |
US14/122,627 US9592286B2 (en) | 2011-05-27 | 2012-05-25 | Combined vaccines for prevention of porcine virus infections |
BR112013030321A BR112013030321A2 (pt) | 2011-05-27 | 2012-05-25 | composição de vacina, método para preparar a composição de vacina, uso da composição de vacina, método para imunizar um porco, cepa de vacina contra csfv e uso de uma célula no cultivo de uma cepa de vacina contra csfv. |
MX2013013906A MX347210B (es) | 2011-05-27 | 2012-05-25 | Vacunas combinadas para prevención de infecciones por virus porcino. |
RU2013158322A RU2628313C2 (ru) | 2011-05-27 | 2012-05-25 | Комбинированные вакцины для профилактики вирусных инфекций свиней |
JP2014511724A JP6096176B2 (ja) | 2011-05-27 | 2012-05-25 | ブタウイルス感染の予防のための混合ワクチン |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110331159.8A CN102727882B (zh) | 2011-10-27 | 2011-10-27 | 猪繁殖与呼吸综合征、猪瘟、伪狂犬病的三联活疫苗及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102727882A CN102727882A (zh) | 2012-10-17 |
CN102727882B true CN102727882B (zh) | 2014-05-14 |
Family
ID=46984643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110331159.8A Active CN102727882B (zh) | 2011-05-27 | 2011-10-27 | 猪繁殖与呼吸综合征、猪瘟、伪狂犬病的三联活疫苗及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102727882B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104511015B (zh) * | 2013-09-30 | 2018-03-02 | 普莱柯生物工程股份有限公司 | 一种疫苗组合物及其制备方法与应用 |
CN106310248B (zh) * | 2015-06-18 | 2019-12-20 | 普莱柯生物工程股份有限公司 | 猪伪狂犬病病毒活疫苗组合物用于治疗猪伪狂犬病的用途 |
CN109758427B (zh) * | 2019-02-26 | 2021-11-02 | 兆丰华生物科技(福州)有限公司 | 一种伪狂犬病活疫苗耐热保护剂及其制备方法和应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0835930A1 (en) * | 1996-10-09 | 1998-04-15 | Akzo Nobel N.V. | European vaccine strains of the porcine reproductive and respiratory syndrome virus (PRRSV) |
EP1792996A1 (en) * | 2005-12-01 | 2007-06-06 | Consejo Superior de Investigaciones Cientificas | Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV) |
CN101633909A (zh) * | 2009-08-13 | 2010-01-27 | 武华 | 预防猪感染猪繁殖与呼吸综合征的减毒活疫苗 |
CN101879311A (zh) * | 2010-06-28 | 2010-11-10 | 武华 | 猪瘟活疫苗的制备方法及其产品 |
CN101991849A (zh) * | 2009-08-18 | 2011-03-30 | 上海科立特农科(集团)有限公司 | 一种猪伪狂犬病灭活疫苗的制备方法 |
-
2011
- 2011-10-27 CN CN201110331159.8A patent/CN102727882B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0835930A1 (en) * | 1996-10-09 | 1998-04-15 | Akzo Nobel N.V. | European vaccine strains of the porcine reproductive and respiratory syndrome virus (PRRSV) |
EP1792996A1 (en) * | 2005-12-01 | 2007-06-06 | Consejo Superior de Investigaciones Cientificas | Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV) |
CN101633909A (zh) * | 2009-08-13 | 2010-01-27 | 武华 | 预防猪感染猪繁殖与呼吸综合征的减毒活疫苗 |
CN101991849A (zh) * | 2009-08-18 | 2011-03-30 | 上海科立特农科(集团)有限公司 | 一种猪伪狂犬病灭活疫苗的制备方法 |
CN101879311A (zh) * | 2010-06-28 | 2010-11-10 | 武华 | 猪瘟活疫苗的制备方法及其产品 |
Also Published As
Publication number | Publication date |
---|---|
CN102727882A (zh) | 2012-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6096176B2 (ja) | ブタウイルス感染の予防のための混合ワクチン | |
CN105087506B (zh) | 一种猪伪狂犬病病毒致弱方法、及其致弱的病毒株、疫苗组合物和应用 | |
CN104004774B (zh) | 一种猪伪狂犬病病毒、疫苗组合物及其制备方法和应用 | |
CN102250843B (zh) | 猪繁殖与呼吸综合征病毒基因工程标记弱毒疫苗株及应用 | |
CN102949718B (zh) | 猪传染性胃肠炎病毒、猪流行性腹泻病毒和猪轮状病毒的三联活疫苗 | |
CN103923884B (zh) | 一种猪伪狂犬病病毒基因缺失株、疫苗组合物及其制备方法和应用 | |
CN102727884B (zh) | 猪繁殖与呼吸综合征、伪狂犬病二联活疫苗及其制备方法 | |
CN109439634A (zh) | 伪狂犬病病毒基因工程弱毒疫苗株及其应用 | |
CN104784686A (zh) | Tgev、pedv二联活疫苗及其制备方法 | |
CN106148287A (zh) | 猪流行性腹泻病毒株及其疫苗组合物、制备方法和应用 | |
CN107537031A (zh) | 一种预防猪繁殖与呼吸综合征的疫苗组合物及其制备方法和应用 | |
CN111876391A (zh) | 猫泛白细胞减少症病毒fpv bj05株及其应用 | |
CN102727883B (zh) | 猪繁殖与呼吸综合征与猪瘟二联疫苗及其用途 | |
CN101376878B (zh) | 猪繁殖与呼吸综合征病毒毒株及由其制备的灭活疫苗 | |
CN102727882B (zh) | 猪繁殖与呼吸综合征、猪瘟、伪狂犬病的三联活疫苗及其制备方法 | |
CN108251382B (zh) | 一种猪伪狂犬病病毒致弱方法、及其致弱的病毒株、疫苗组合物和应用 | |
CN105802921B (zh) | 表达猪瘟病毒e2蛋白的重组伪狂犬病病毒变异株及其构建方法和应用 | |
CN105200015B (zh) | 一种猪伪狂犬病毒株 | |
CN104288760A (zh) | 一种疫苗组合物及其制备方法和应用 | |
Abisheva et al. | AK‐2011 strain for the development of a vaccine against equine rhinopneumonitis | |
CN104328090B (zh) | 一种猪伪狂犬病病毒株、疫苗组合物及其制备方法和应用 | |
CN103740653A (zh) | 一株猪传染性胃肠炎病毒及其应用 | |
CN103041384B (zh) | 一种疫苗组合物及其制备方法和应用 | |
Lei et al. | Porcine Epidemic Diarrhea Virus: Etiology, Epidemiology, Antigenicity, and Control Strategies in China | |
CN116426487A (zh) | 一种猪流行性腹泻病毒株及其在疫苗制备中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SINOVET (JIANGSU) BIOPHARMACEUTICAL CO., LTD. Effective date: 20130327 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20130327 Address after: 100085 B302 room three, B District, Zhongguancun biomedicine Park, 5 Haidian District Road, Beijing, China Applicant after: Sinovet (Beijing) Biotechnology Co., Ltd. Applicant after: SINOVET (JIANGSU) BIOTECHNOLOGY CO., LTD. Address before: 100085 B302 room three, B District, Zhongguancun biomedicine Park, 5 Haidian District Road, Beijing, China Applicant before: Sinovet (Beijing) Biotechnology Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Wu Hua Inventor after: Wang Wei Inventor after: Xia Mingqi Inventor after: Wang Xin Inventor before: Wu Hua |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WU HUA TO: WU HUA WANG WEI XIA MINGQI WANG XIN |
|
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Wu Hua Inventor after: Wang Wei Inventor after: Xia Mingqi Inventor after: Wang Xin Inventor after: Zhao Jianzeng Inventor before: Wu Hua Inventor before: Wang Wei Inventor before: Xia Mingqi Inventor before: Wang Xin |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WU HUA WANG WEI XIA MINGQI WANG XIN TO: WU HUA WANG WEI XIA MINGQI WANG XIN ZHAO JIANZENG |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170904 Address after: 388 room 1, building 225300, No.1 drug City Avenue, Taizhou, Jiangsu Patentee after: SINOVET (JIANGSU) BIOTECHNOLOGY CO., LTD. Address before: 100085 B302 room three, B District, Zhongguancun biomedicine Park, 5 Haidian District Road, Beijing, China Co-patentee before: SINOVET (JIANGSU) BIOTECHNOLOGY CO., LTD. Patentee before: Sinovet (Beijing) Biotechnology Co., Ltd. |
|
CP02 | Change in the address of a patent holder |
Address after: 225300, 409 Gao Jiang Road, Jiangsu, Taizhou Patentee after: SINOVET (JIANGSU) BIOTECHNOLOGY CO., LTD. Address before: 388 room 1, building 225300, No.1 drug City Avenue, Taizhou, Jiangsu Patentee before: SINOVET (JIANGSU) BIOTECHNOLOGY CO., LTD. |
|
CP02 | Change in the address of a patent holder |